← Leaderboards
Robert J Coffey
Vanderbilt University
$53,530,293
Attributed
$58,017,607
Total exposure
35
Grants
31
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$124,115,280 · 38
VA$0 · 1
By mechanism
P50$57,740,863 · 15
R01$17,095,803 · 5
U2C$15,420,300 · 2
U19$10,323,223 · 4
R35$8,367,059 · 1
U01$8,038,617 · 1
Top collaborators
- Michael Gerdes5 shared
- Kevin Michael Haigis5 shared
- Alain Charest4 shared
- Lynn M Matrisian4 shared
- Martha J. Shrubsole3 shared
- Ken S Lau2 shared
- Kashan Shaikh1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Charles R Flynn$1,492,514
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorColorectal CancerMalignant NeoplasmsCellsBaseSignal TransductionColon CarcinomaEpidermal Growth Factor ReceptorTissuesStem CellsTumor ProgressionProgramsProteinsColonResourcesCancer CellKras2 GeneResearch PersonnelPathway InteractionsRegulationMouse ModelMutantIn VivoReporting
Grant awards (169)
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$2,398,107
P50 · FY2025 · CA · contact PI
Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation$915,790
R35 · FY2025 · CA · contact PI
Project 1: Overcoming Immune Exclusion in Microsatellite Stable Colorectal Cancer$381,800
P50 · FY2025 · CA · contact PI
Shaping the Microenvironment by DPEP1 Facilitates Adenoma Progression$281,177
U54 · FY2025 · CA · contact PI
Administrative Core$262,213
P50 · FY2025 · CA · contact PI
Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation$1,062,441
R35 · FY2024 · CA · contact PI
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$896,274
P50 · FY2024 · CA · contact PI
Shaping the Microenvironment by DPEP1 Facilitates Adenoma Progression$603,822
U54 · FY2024 · CA · contact PI
Role of WNT-EGFR crosstalk by EVs and exomeres in normal colon and colon cancer$335,100
P01 · FY2024 · CA · contact PI
Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC$275,447
P50 · FY2024 · CA · contact PI
Administrative Core$81,071
P50 · FY2024 · CA · contact PI
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$2,278,912
P50 · FY2023 · CA · contact PI
Administrative Core$1,040,698
U2C · FY2023 · CA · contact PI
Integrative Single-Cell Atlas of Host and Microenvironment in Colorectal Neoplastic Transformation$1,040,698
U2C · FY2023 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$915,799
R35 · FY2023 · CA · contact PI
Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC$389,369
P50 · FY2023 · CA · contact PI
Shaping the Microenvironment by DPEP1 Facilitates Adenoma Progression$379,488
U54 · FY2023 · CA · contact PI
Role of WNT-EGFR crosstalk by EVs and exomeres in normal colon and colon cancer$345,683
P01 · FY2023 · CA · contact PI
Administrative Core$188,274
P50 · FY2023 · CA · contact PI
Distribution of Molecular Features for Colorectal Cancers in Northern Tanzania$125,000
P50 · FY2023 · CA · contact PI
Administrative Core$125,000
P50 · FY2023 · CA · contact PI
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$2,287,595
P50 · FY2022 · CA · contact PI
Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasma$1,049,684
UH3 · FY2022 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$869,666
R35 · FY2022 · CA · contact PI
Shaping the Microenvironment by DPEP1 Facilitates Adenoma Progression$474,565
U54 · FY2022 · CA · contact PI
Role of WNT-EGFR crosstalk by EVs and exomeres in normal colon and colon cancer$405,935
P01 · FY2022 · CA · contact PI
Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC$389,369
P50 · FY2022 · CA · contact PI
Administrative Core$188,274
P50 · FY2022 · CA · contact PI
Administrative Core$112,747
U54 · FY2022 · CA · contact PI
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$2,276,968
P50 · FY2021 · CA · contact PI
Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasma$1,049,684
UH3 · FY2021 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$845,075
R35 · FY2021 · CA · contact PI
Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC$399,199
P50 · FY2021 · CA · contact PI
Role of WNT-EGFR crosstalk by EVs and exomeres in normal colon and colon cancer$352,736
P01 · FY2021 · CA · contact PI
Integrative Single-Cell Atlas of Host and Microenvironment in Colorectal Neoplastic Transformation$211,782
U2C · FY2021 · CA · contact PI
Administrative Core$182,964
P50 · FY2021 · CA · contact PI
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$2,379,065
P50 · FY2020 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$944,082
R35 · FY2020 · CA · contact PI
Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasma$516,236
UG3 · FY2020 · CA · contact PI
Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC$404,764
P50 · FY2020 · CA · contact PI
Role of WNT-EGFR crosstalk by EVs and exomeres in normal colon and colon cancer$367,236
P01 · FY2020 · CA · contact PI
Administrative Core$188,529
P50 · FY2020 · CA · contact PI
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal Cancer$2,368,006
P50 · FY2019 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$918,902
R35 · FY2019 · CA · contact PI
Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasma$533,736
UG3 · FY2019 · CA · contact PI
Project 1: Interrogating Distinct Tumor-Initiating Cells in CRC$400,209
P50 · FY2019 · CA · contact PI
Administrative Core$189,516
P50 · FY2019 · CA · contact PI
Integrative Single-Cell Atlas of Host and Microenvironment in Colorectal Neoplastic Transformation$10,993,061
U2C · FY2018 · CA · contact PI
Administrative Core$2,134,061
U2C · FY2018 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$947,652
R35 · FY2018 · CA · contact PI
Secreted RNA during CRC progression biogenesis function and clinical markers$964,438
U19 · FY2017 · CA · contact PI
Integrated approach to study early and late events in colonic neoplasia: mouse to man$947,652
R35 · FY2017 · CA · contact PI
SPORE in GI Cancer$709,080
P50 · FY2017 · CA · contact PI
Functional changes in secreted RNA biogenesis using in vivo colon tumor models$434,892
U19 · FY2017 · CA · contact PI
Trafficking of eRNAs in K-Ras Mutant Colon Cancer$368,971
U19 · FY2017 · CA · contact PI
Biotechnology and Bioinformatics Core$160,575
U19 · FY2017 · CA · contact PI
SPORE in GI Cancer$2,033,881
P50 · FY2016 · CA · contact PI
Secreted RNA during CRC progression biogenesis function and clinical markers$1,048,240
U19 · FY2016 · CA · contact PI
Validation of a single cell multiplexed in-situ biomarker analysis platform for p$750,001
R01 · FY2016 · CA
Roles for Lrig1 in Intestinal Neoplasia$470,011
R01 · FY2016 · CA · contact PI
Role of EGFR Ligands in Neoplasia$468,846
R01 · FY2016 · CA · contact PI
Functional changes in secreted RNA biogenesis using in vivo colon tumor models$467,369
U19 · FY2016 · CA · contact PI
Role of EGFR ligand-containing exosomes in colorectal cancer$439,496
R01 · FY2016 · CA · contact PI
Trafficking of eRNAs in K-Ras Mutant Colon Cancer$401,745
U19 · FY2016 · CA · contact PI
Biotechnology and Bioinformatics Core$179,126
U19 · FY2016 · CA · contact PI
ADMINISTRATIVE SUPPLEMENT - Secreted RNA during CRC progression: biogenesis, function and clinical markers$79,000
U19 · FY2016 · CA · contact PI
Role of EGFR Ligands in Neoplasia$42,082
R01 · FY2016 · CA · contact PI
SPORE in GI Cancer$2,055,518
P50 · FY2015 · CA · contact PI
Validation of a single cell multiplexed in-situ biomarker analysis platform for p$750,000
R01 · FY2015 · CA
Secreted RNA during CRC progression biogenesis function and clinical markers$539,241
U19 · FY2015 · CA · contact PI
Role of EGFR Ligands in Neoplasia$504,994
R01 · FY2015 · CA · contact PI
Secreted RNA during CRC progression biogenesis function and clinical markers$470,093
U19 · FY2015 · CA · contact PI
Functional changes in secreted RNA biogenesis using in vivo colon tumor models$455,136
U19 · FY2015 · CA · contact PI
Role of EGFR ligand-containing exosomes in colorectal cancer$413,628
R01 · FY2015 · CA · contact PI
Trafficking of eRNAs in K-Ras Mutant Colon Cancer$386,150
U19 · FY2015 · CA · contact PI
Molecular Imaging & Targeted Therapeutics of Stem Cell-Derived Colon Cancer$288,139
P50 · FY2015 · CA · contact PI
Administrative Core$203,591
P50 · FY2015 · CA · contact PI
Biotechnology and Bioinformatics Core$168,048
U19 · FY2015 · CA · contact PI
The Role of EGFR Negative Regulators in GI Neoplasia$0
I01 · FY2015 · VA · contact PI
SPORE in GI Cancer$1,937,245
P50 · FY2014 · CA · contact PI
Secreted RNA during CRC progression biogenesis function and clinical markers$1,042,100
U19 · FY2014 · CA · contact PI
Molecular Imaging & Targeted Therapeutics of Stem Cell-Derived Colon Cancer$916,239
P50 · FY2014 · CA · contact PI
Validation of a single cell multiplexed in-situ biomarker analysis platform for p$750,002
R01 · FY2014 · CA
Role of EGFR Ligands in Neoplasia$539,845
R01 · FY2014 · CA · contact PI
Role of EGFR ligand-containing exosomes in colorectal cancer$468,372
R01 · FY2014 · CA · contact PI
Functional changes in secreted RNA biogenesis using in vivo colon tumor models$459,488
U19 · FY2014 · CA · contact PI
Trafficking of eRNAs in K-Ras Mutant Colon Cancer$388,264
U19 · FY2014 · CA · contact PI
Cell-of-origin effects on development of colon cancer$365,423
R01 · FY2014 · CA · contact PI
Biotechnology and Bioinformatics Core$163,083
U19 · FY2014 · CA · contact PI
Administrative Core$112,543
P50 · FY2014 · CA · contact PI
Secreted RNA during CRC progression biogenesis function and clinical markers$78,500
U19 · FY2014 · CA · contact PI
Analysis of Serum Exosomes in Patients with Colorectal and Breast Cancer$8,321
U54 · FY2014 · CA · contact PI
The Role of EGFR Negative Regulators in GI Neoplasia$0
I01 · FY2014 · VA · contact PI
SPORE in GI Cancer$1,612,852
P50 · FY2013 · CA · contact PI
Secreted RNA during CRC progression biogenesis function and clinical markers$1,034,382
U19 · FY2013 · CA · contact PI
Molecular Imaging & Targeted Therapeutics of Stem Cell-Derived Colon Cancer$917,743
P50 · FY2013 · CA · contact PI
Validation of a single cell multiplexed in-situ biomarker analysis platform for p$727,501
R01 · FY2013 · CA
Role of EGFR Ligands in Neoplasia$474,694
R01 · FY2013 · CA · contact PI
Functional changes in secreted RNA biogenesis using in vivo colon tumor models$466,431
U19 · FY2013 · CA · contact PI
Role of EGFR ligand-containing exosomes in colorectal cancer$413,628
R01 · FY2013 · CA · contact PI
Trafficking of eRNAs in K-Ras Mutant Colon Cancer$395,732
U19 · FY2013 · CA · contact PI
Cell-of-origin effects on development of colon cancer$354,120
R01 · FY2013 · CA · contact PI
Biotechnology and Bioinformatics Core$172,219
U19 · FY2013 · CA · contact PI
Administrative Core$119,802
P50 · FY2013 · CA · contact PI
Analysis of Serum Exosomes in Patients with Colorectal and Breast Cancer$57,816
U54 · FY2013 · CA · contact PI
The Role of EGFR Negative Regulators in GI Neoplasia$0
I01 · FY2013 · VA · contact PI
SPORE in GI Cancer$2,300,000
P50 · FY2012 · CA · contact PI
Molecular Imaging & Targeted Therapeutics of Stem Cell-Derived Colon Cancer$1,051,262
P50 · FY2012 · CA · contact PI
Validation of a single cell multiplexed in-situ biomarker analysis platform for p$749,997
R01 · FY2012 · CA
Role of EGFR Ligands in Neoplasia$504,994
R01 · FY2012 · CA · contact PI
Cell-of-origin effects on development of colon cancer$376,724
R01 · FY2012 · CA · contact PI
Administrative Core$137,232
P50 · FY2012 · CA · contact PI
Molecular Imaging to Evaluate EGFR and SRC Targeted Therapies in Colorectal....$104,953
P50 · FY2012 · CA · contact PI
Analysis of Serum Exosomes in Patients with Colorectal and Breast Cancer$62,115
U54 · FY2012 · CA · contact PI
The Role of EGFR Negative Regulators in GI Neoplasia$0
I01 · FY2012 · VA · contact PI
SPORE in Gl Cancer$2,164,394
P50 · FY2011 · CA · contact PI
Cell-of-origin effects on development of colon cancer$376,150
R01 · FY2011 · CA · contact PI
Molecular Imaging to Evaluate EGFR and SRC Targeted Therapies in Colorectal....$116,279
P50 · FY2011 · CA · contact PI
Developmental Research Program$107,998
P50 · FY2011 · CA · contact PI
Analysis of Serum Exosomes in Patients with Colorectal and Breast Cancer$62,400
U54 · FY2011 · CA · contact PI
SPORE in Gl Cancer$2,278,307
P50 · FY2010 · CA · contact PI
Role of EGFR Ligands in Neoplasia$581,668
R01 · FY2010 · CA · contact PI
Cell-of-origin effects on development of colon cancer$184,720
R01 · FY2010 · CA · contact PI
Molecular Imaging to Evaluate EGFR and SRC Targeted Therapies in Colorectal....$142,869
P50 · FY2010 · CA · contact PI
Developmental Research Program$116,137
P50 · FY2010 · CA · contact PI
SPORE in Gl Cancer$2,278,307
P50 · FY2009 · CA · contact PI
Role of EGFR Ligands in Neoplasia$571,939
R01 · FY2009 · CA · contact PI
Role of EGFR Ligands in Neoplasia$332,016
R01 · FY2009 · CA · contact PI
Prevention & Metastasis: Final Frontiers in Colon Cancer$224,953
U01 · FY2009 · CA · contact PI
Molecular Imaging to Evaluate EGFR and SRC Targeted Therapies in Colorectal....$139,907
P50 · FY2009 · CA · contact PI
Developmental Research Program$118,643
P50 · FY2009 · CA · contact PI
SPORE in Gl Cancer$2,278,307
P50 · FY2008 · CA · contact PI
Prevention & Metastasis: Final Frontiers in Colon Cancer$1,051,364
U01 · FY2008 · CA · contact PI
Role of EGFR Ligands in Neoplasia$556,959
R01 · FY2008 · CA · contact PI
Developmental Research Program$121,173
P50 · FY2008 · CA · contact PI
Molecular Imaging to Evaluate EGFR and SRC Targeted Therapies in Colorectal....$90,412
P50 · FY2008 · CA · contact PI
COMPASSIONATE USE OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY C225$1,558
M01 · FY2008 · RR · contact PI
SPORE in Gl Cancer$2,278,307
P50 · FY2007 · CA · contact PI
Prevention & Metastasis: Final Frontiers in Colon Cancer$832,322
U01 · FY2007 · CA · contact PI
Role of EGFR Ligands in Neoplasia$552,554
R01 · FY2007 · CA · contact PI
Studies on the Stem Cells of the Colonic Mucosa$336,463
R01 · FY2007 · DK · contact PI
Administrative$179,493
P50 · FY2007 · CA · contact PI
Developmental Research Program$114,312
P50 · FY2007 · CA · contact PI
COMPASSIONATE USE OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY C225$33,068
M01 · FY2007 · RR · contact PI
SPORE in Gl Cancer$2,365,287
P50 · FY2006 · CA · contact PI
Prevention & Metastasis: Final Frontiers in Colon Cancer$835,111
U01 · FY2006 · CA · contact PI
Role of EGFR Ligands in Neoplasia$552,136
R01 · FY2006 · CA · contact PI
Studies on the Stem Cells of the Colonic Mucosa$346,512
R01 · FY2006 · DK · contact PI
SPORE in Gl Cancer$50,400
P50 · FY2006 · CA · contact PI
COMPASSIONATE USE OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY C225$35,236
M01 · FY2006 · RR · contact PI
SPORE in Gl Cancer$2,422,791
P50 · FY2005 · CA
Prevention &Metastasis: Final Frontiers in Colon Cancer$833,263
U01 · FY2005 · CA
Role of EGF Receptor Ligands in Neoplasia$556,926
R01 · FY2005 · CA
SPORE in Gl Cancer$2,400,582
P50 · FY2004 · CA
Prevention &Metastasis: Final Frontiers in Colon Cancer$850,000
U01 · FY2004 · CA
Role of EGF Receptor Ligands in Neoplasia$540,708
R01 · FY2004 · CA
Compassionate use of Anti-Epidermal Growth Factor Receptor Antibody C225$61,072
M01 · FY2004 · RR
SPORE in Gl Cancer$2,427,218
P50 · FY2003 · CA
MOUSE CANCER MODELS VIA TGF-BETA RII LOSS$888,503
U01 · FY2003 · CA
Role of EGF Receptor Ligands in Neoplasia$524,958
R01 · FY2003 · CA
SPORE in Gl Cancer$1,993,735
P50 · FY2002 · CA
MOUSE CANCER MODELS VIA TGF-BETA RII LOSS$997,931
U01 · FY2002 · CA
Role of EGF Receptor Ligands in Neoplasia$510,088
R01 · FY2002 · CA
COMBINED BLOCKADE OF EGF RECEPTOR AND COX-2 IN INTESTINAL TUMORIGENESIS$0
P50 · FY2002 · CA
EGFR AXIS AS A THERAPEUTIC TARGET IN COLORECTAL CANCER$0
P50 · FY2002 · CA
MOUSE CANCER MODELS VIA TGF-BETA RII LOSS$858,135
U01 · FY2001 · CA
Role of EGF Receptor Ligands in Neoplasia$496,459
R01 · FY2001 · CA
MOUSE CANCER MODELS VIA TGF-BETA RII LOSS$667,035
U01 · FY2000 · CA
TRANSFORMING GROWTH FACTOR ALPHA AND NEOPLASIA$511,189
R01 · FY2000 · CA